Coagulation Factor VIII
EstablishedFactor VIII deficiency causes Hemophilia A; treatment has shifted toward non-factor replacement therapies.
Factor VIII deficiency causes Hemophilia A. Treatment has moved well beyond simple factor replacement — newer drugs mimic factor VIII's clotting function with far less frequent dosing, dramatically improving patients' quality of life compared to older twice- or thrice-weekly infusions.
Factor VIII is a clotting protein whose deficiency causes Hemophilia A, the most common severe inherited bleeding disorder, historically treated with factor replacement infusions.
Low Factor VIII activity confirms Hemophilia A and its severity; treatment has shifted dramatically toward non-factor replacement therapies that mimic factor VIII's clotting function without requiring the protein itself.
Measured via specific factor VIII clotting assay; F8 gene testing confirms diagnosis. A key laboratory complication: emicizumab (a common non-factor therapy) interferes with standard factor VIII activity assays, requiring specialized chromogenic assays to accurately measure other therapies in patients already on it.
Emicizumab (a bispecific antibody mimicking factor VIII function) has become mainstream therapy; 2023's efanesoctocog alfa offers weekly dosing with sustained factor activity, a major quality-of-life improvement over older products needing 2-3x weekly infusions. 2025 data showed newer pipeline agents (denecimig, NXT007) allowing direct switching from emicizumab without a washout period.
Emicizumab and newer agents have transformed treatment convenience; lab testing requires specialized assays in these patients.
- Rare Disease Advisor. (2025). Highlights From ISTH 2025: Treatment Advances in Hemophilia A.
- PMC. (2024). Emicizumab: the hemophilia A game-changer.